A unique study by researchers at the University of York and Hull York Medical School has confirmed a link between depression and low levels of folate, a vitamin which comes from vegetables.
Researchers at the Picower Institute at MIT have, for the first time, reversed symptoms of mental retardation and autism in mice. The study may lead to new drug therapies for a leading inherited cause of mental retardation (Fragile X Syndrome) and some types of autism.
Researchers at the University of Pennsylvania say that practicing even small doses of daily meditation may improve focus and performance. Meditation, according to Penn neuroscientist Amishi Jha and Michael Baime, director of Penn’s Stress Management Program, is an active and effortful process that literally changes the way the brain works.
Cyclical, long-term estrogen injections protected brain cells from age-related deterioration, according to a new study conducted at Mount Sinai School of Medicine. The study suggests that age is a factor in estrogen treatment and sheds light on the intricate relationship between mind, age, and hormones. The study will be published in the online edition of Proceedings of the National Academy of Sciences during the week of June 25.
The first-ever phase 1 clinical trial using gene therapy to battle Parkinson’s disease is completed by a team led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Fibromyalgia, a chronic, widespread pain in muscles and soft tissues accompanied by fatigue, is a fairly common condition that does not manifest any structural damage in an organ. Twenty-five years ago, Muhammad B. Yunus, MD, and colleagues published the first controlled study of the clinical characteristics of fibromyalgia syndrome.
Scientists at the University of Virginia and the Medical College of Wisconsin have discovered that a gene that participates in the regulation of the body?s biological rhythms may also be a major control in regulating metabolism.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist that has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
amfAR, The Foundation for AIDS Research, will grant almost $1.2 million for 10 new research projects aimed at increasing understanding of the social and biological factors that influence the treatment of HIV/AIDS, Dr. Rowena Johnston, amfAR?s vice president of research.
A pair of new vaccines designed to combat cocaine and methamphetamine dependencies not only relieve addiction but also minimize withdrawal symptoms, according to study results presented today by Baylor College of Medicine (BCM) researchers at the Annual Meeting of the College on Problems of Drug Dependence in Quebec City, Canada.